Denise Trone

1.9k total citations
27 papers, 1.1k citations indexed

About

Denise Trone is a scholar working on Genetics, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Denise Trone has authored 27 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Genetics, 22 papers in Hematology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Denise Trone's work include Acute Myeloid Leukemia Research (22 papers), Chronic Myeloid Leukemia Treatments (21 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Denise Trone is often cited by papers focused on Acute Myeloid Leukemia Research (22 papers), Chronic Myeloid Leukemia Treatments (21 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Denise Trone collaborates with scholars based in United States, United Kingdom and France. Denise Trone's co-authors include Guy Gammon, Jörge E. Cortes, Mark J. Levis, James M. Foran, Alexander E. Perl, Giovanni Martinelli, Hagop M. Kantarjian, Martin S. Tallman, Robert C. Armstrong and Joyce James and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Denise Trone

27 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Denise Trone United States	13	981	448	400	164	102	27	1.1k
Olga Salamero Spain	13	625 0.6×	381 0.9×	282 0.7×	180 1.1×	167 1.6×	46	890
Andrew Kuykendall United States	14	621 0.6×	385 0.9×	512 1.3×	44 0.3×	136 1.3×	174	839
Sara Dellasala United States	11	622 0.6×	207 0.5×	388 1.0×	91 0.6×	92 0.9×	33	695
S. Kurtin United States	3	554 0.6×	280 0.6×	250 0.6×	59 0.4×	77 0.8×	8	674
Fabio P S Santos United States	10	374 0.4×	171 0.4×	203 0.5×	90 0.5×	99 1.0×	16	520
François G. Kavelaars Netherlands	9	429 0.4×	308 0.7×	204 0.5×	62 0.4×	61 0.6×	24	645
Jing-Zhou Hou United States	2	418 0.4×	268 0.6×	115 0.3×	115 0.7×	99 1.0×	3	498
Alice Marceau‐Renaut France	11	400 0.4×	200 0.4×	143 0.4×	97 0.6×	48 0.5×	42	505
Jennifer L. Rocnik United States	9	357 0.4×	273 0.6×	142 0.4×	75 0.5×	100 1.0×	12	553
MV Mateos Spain	12	650 0.7×	261 0.6×	97 0.2×	163 1.0×	263 2.6×	37	750

Countries citing papers authored by Denise Trone

Since Specialization

Citations

This map shows the geographic impact of Denise Trone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denise Trone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denise Trone more than expected).

Fields of papers citing papers by Denise Trone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denise Trone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denise Trone. The network helps show where Denise Trone may publish in the future.

Co-authorship network of co-authors of Denise Trone

This figure shows the co-authorship network connecting the top 25 collaborators of Denise Trone. A scholar is included among the top collaborators of Denise Trone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denise Trone. Denise Trone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Besse, Benjamin, Christina S. Baik, Christoph Springfeld, et al.. (2021). Abstract P02-01: Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial. Molecular Cancer Therapeutics. 20(12_Supplement). P02–1. 4 indexed citations

Linehan, W. Marston, Byoung Chul Cho, Christoph Springfeld, et al.. (2021). Abstract P224: Update from the Phase 2 registrational trial of repotrectinib in TKI-pretreated patients with ROS1+ advanced non-small cell lung cancer and with NTRK+ advanced solid tumors (TRIDENT-1). Molecular Cancer Therapeutics. 20(12_Supplement). P224–P224. 2 indexed citations

Li, Jianke, Melissa F. Holmes, Martin Kankam, et al.. (2020). Effect of Food on the Pharmacokinetics of Quizartinib. Clinical Pharmacology in Drug Development. 9(2). 277–286. 9 indexed citations

Li, Jianke, Denise Trone, Jeanne Mendell, Patrick W. O’Donnell, & Natalie Cook. (2019). A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics. Cancer Chemotherapy and Pharmacology. 84(4). 799–807. 11 indexed citations

Li, Jianke, Martin Kankam, Denise Trone, & Guy Gammon. (2019). Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. British Journal of Clinical Pharmacology. 85(9). 2108–2117. 22 indexed citations

Papadopoulos, Kyriakos P., Eytan Ben‐Ami, Amita Patnaik, et al.. (2018). Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial. BMC Cancer. 18(1). 790–790. 8 indexed citations

Altman, Jessica K., James M. Foran, Keith W. Pratz, et al.. (2017). Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology. 93(2). 213–221. 77 indexed citations

Sandmaier, Brenda M., Samer K. Khaled, Betül Oran, et al.. (2017). Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. American Journal of Hematology. 93(2). 222–231. 97 indexed citations

Levis, Mark J., et al.. (2016). Laboratory and Clinical Investigations to Identify the Optimal Dosing Strategy for Quizartinib (AC220) Monotherapy in FLT3-Itd-Positive (+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Blood. 128(22). 4042–4042. 16 indexed citations

10.

Hills, Robert K., Guy Gammon, Denise Trone, & Alan K. Burnett. (2015). Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical AML Database (UK NCRI data). Blood. 126(23). 2557–2557. 10 indexed citations

11.

Awan, Farrukh T., Peter Hillmen, Andrzej Hellmann, et al.. (2014). A randomized, open‐label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 167(4). 466–477. 25 indexed citations

12.

Martinelli, Giovanni, Mark J. Levis, Alexander E. Perl, et al.. (2014). Treatment With Quizartinib (AC220) Enables a High Rate of Patients With Relapsed or Refractory FLT3-ITD(+) Acute Myeloid Leukemia to be Bridged to HSCT. 1 indexed citations

13.

Levis, Mark J., Giovanni Martinelli, Alexander E. Perl, et al.. (2014). The benefit of treatment with quizartinib and subsequent bridging to HSCT for FLT3-ITD(+) patients with AML.. Journal of Clinical Oncology. 32(15_suppl). 7093–7093. 8 indexed citations

14.

Sandmaier, Brenda M., Samer K. Khaled, Betül Oran, et al.. (2014). Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation. Blood. 124(21). 428–428. 31 indexed citations

15.

Altman, Jessica K., James M. Foran, Keith W. Pratz, et al.. (2013). Results Of a Phase 1 Study Of Quizartinib (AC220, ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With Newly Diagnosed Acute Myeloid Leukemia. Blood. 122(21). 623–623. 16 indexed citations

16.

Cortes, Jörge E., Hagop M. Kantarjian, James M. Foran, et al.. (2013). Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status. Journal of Clinical Oncology. 31(29). 3681–3687. 278 indexed citations

17.

Cortes, Jörge E., Alexander E. Perl, Hervé Dombret, et al.. (2013). Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory AML after second-line chemotherapy or previous bone marrow transplant.. Journal of Clinical Oncology. 31(15_suppl). 7012–7012. 6 indexed citations

18.

Cortes, Jörge E., Alexander E. Perl, Hervé Dombret, et al.. (2012). Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia. Blood. 120(21). 48–48. 104 indexed citations

19.

Cortes, Jörge E., Hagop M. Kantarjian, James M. Foran, et al.. (2012). Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status. Blood. 120(21). 1507–1507. 4 indexed citations

20.

Hoff, Daniel D. Von, M. Beeram, Januario E. Castro, et al.. (2007). Phase 1 experience with BIIB021, an oral, synthetic, non-ansamycin Hsp90 inhibitor. Molecular Cancer Therapeutics. 6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact